BioStock: Chordate Medical publishes interim report and looks forward

At the end of last week, Chordate Medical published their results for the first nine months of 2020. The report shows that the company’s sales and operations have been affected by the pandemic, but despite this, Chordate Medical has high confidence going forward. The company’s financial position has recently been strengthened by two successful capital raises. In addition, a CE mark is waiting around the corner which enables start of sales within a new indication with great potential – chronic migraine.

Read the full article at biostock.se:

https://www.biostock.se/en/chordate-medical-publishes-interim-report-and-looks-forward/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se